CD226 Inhibitors Block Platelet-Tumor Interaction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-tumor metastasis treatments using platelet inhibitors, such as cyclooxygenase inhibitors, ADP P2Y12 receptor antagonists, and platelet protease-activated receptor-1 inhibitors, have significant side effects due to their impact on normal physiological functions of platelets, necessitating the development of less side-effect-intensive solutions.
Innovation Solution
Targeting CD226 molecules on platelets with small-molecule inhibitors like angiotensin III, neohesperidin, [Leu5]-enkephalin, epimedin B, methylhesperidin, salvianolic acid B, bradykinin (2-9), echinacoside, and astragaloside III or poliumoside to interfere with platelet activation and inhibit tumor metastasis, while minimizing disruption to normal platelet functions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If cyclooxygenase inhibitors, ADP P2Y12 receptor antagonists, or platelet protease-activated receptor-1 inhibitors are used to inhibit tumor metastasis, then tumor metastasis is suppressed, but normal physiological functions of platelets are disrupted causing significant side effects
Solution Approach 1:
The patent introduces CD226 molecules as a specific intermediary target on platelets that mediate tumor cell interaction. By designing inhibitors that specifically bind to CD226, the treatment interrupts the harmful platelet-tumor interaction while leaving other normal platelet functions intact, thus resolving the contradiction between suppressing metastasis and maintaining physiological functions
Solution Approach 2:
The invention applies local quality by targeting a specific molecular component (CD226) on platelets rather than globally inhibiting all platelet functions. This localized targeting approach allows selective interference with tumor-promoting activities while preserving other essential platelet functions such as hemostasis and vascular repair
2Reliability
If broad-spectrum platelet inhibitors are used to prevent tumor metastasis, then metastasis risk is reduced, but hemostasis and vascular repair functions are compromised
Solution Approach 1:
CD226 molecules serve as a specific intermediary that facilitates the interaction between activated platelets and tumor cells. By targeting this intermediary with selective inhibitors, the patent achieves reliable anti-metastasis efficacy while avoiding disruption of other normal platelet functions, thus maintaining ease of physiological operations like hemostasis
3Object-affected harmful factors
If existing platelet inhibitors are used to block tumor-platelet interaction, then tumor growth and angiogenesis are suppressed, but normal platelet activities are significantly affected
Solution Approach 1:
The patent applies local quality by specifically targeting CD226 molecules on platelets, which are locally involved in tumor-promoting interactions. This selective localization allows suppression of tumor progression through inhibition of platelet-tumor adhesion while preserving other normal platelet activities that do not involve CD226
Solution Approach 2:
CD226 acts as a specific intermediary molecule that mediates the harmful interaction between platelets and tumor cells. The inhibitors designed in this patent specifically block this intermediary function, thereby suppressing tumor progression without affecting other normal platelet activities that proceed through different molecular pathways
Data Source
AI summary
The present disclosure relates to the field of biotechnology, and in particular to an application of inhibitors targeting CD226 molecules in anti-tumor metastasis. In view of the important role of platelets in mediating tumor metastasis, the present disclosure develops small-molecule inhibitors with blocking effects by targeting CD226 molecules, an important target. It can destroy the interaction between platelets and tumor cells, and inhibit the metastasis of tumor cells, and it is important for research and development of new methods to control tumor metastasis.